Artiva Biotherapeutics (NASDAQ:ARTV) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) in a report released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $23.00 target price on the stock. A number of other brokerages have also issued reports on ARTV. Wedbush initiated coverage on shares […]

Leave a Reply

Your email address will not be published.

Previous post Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com
Next post Autodesk (NASDAQ:ADSK) Price Target Raised to $300.00